目的 通过阐述冻干注射剂辅料选择的基本考虑,为药学开发提供借鉴和思考。方法 汇总了近年来FDA已上市化药冻干注射剂的辅料使用情况,包括辅料组成、FDA收载的最大辅料用量等,论述冻干注射剂辅料选择需重点考虑的问题。结果 已上市冻干注射剂中有四分之一不使用辅料,而使用最多的辅料类别分别是冻干赋形剂、缓冲盐和pH调节剂,其他辅料包括增加溶解的辅料、抗氧剂等。结论 冻干注射剂辅料的选择要重点考虑安全性、处方合理性、功能性指标及辅料控制方面的问题。
Abstract
OBJECTIVE To provide reference and consideration for pharmaceutical development by expounding the basic considerations for the selection of freeze-dried injection excipients. METHODS The excipients in freeze-dried injections approved by FDA in recent years have been listed, and the composition of excipients in the preparations and the maximum amount of excipients contained were summarized. The issues to be considered in the selection of freeze-dried injections were discussed. RESULTS One quarter of the freeze-dried injections that have been marketed do not use excipients, while the most commonly used excipients are bulking agents, buffering agents and pH adjusters. Other excipients include solubilizing agent, antioxidants, etc.. CONCLUSION The selection of freeze-dried injection excipients should focus on safety, formulation rationality, functionality-related characteristics and control of excipients.
关键词
冻干注射剂 /
辅料 /
安全性 /
处方合理性 /
功能性指标
{{custom_keyword}} /
Key words
freeze-dried injection /
excipient /
safety /
formulation rationality /
functionality-related characteristics
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] BAHETI A, KUMAR L, BANSAL A K. Excipients used in lyophilization of small molecules[J]. J Excip Food Chem,2016,1(1):1135.
[2] FDA. Using the Inactive Ingredient Database Guidance for Industry.[EB/OL]. [2019-07]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-inactive-ingredient-database-guidance-industry.
[3] JENNINGS T A. Effect of formulation on lyophilization, part 1[J]. IVD Technol Mag, 1997,3(2):42-49.
[4] FRANKS F, AUFFRET T. Freeze-Drying of Pharmaceuticals and Biopharmaceuticals[M]. Cambridge: RSC Publishing, 2007.
[5] SEARLES J A. Freezing and annealing phenomena in lyophilization, in: L. Rey, J. C. May (Eds.), Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products[M]. New York:Marcel Dekker, Inc., 2004.
[6] JENNINGS T. The importance of process water, in: Lyophilization, Introduction and Basic Principles[M]. Englewood:Interpharm Press, 1999.
[7] PATEL S M, PANSARE S K. Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents, 2017.
[8] GOMEZ G, PIKAL M J, RODRIGUEZ-HORNEDO N. Effect of initial buffer composition on pH changes during far-fromequilibrium freezing of sodium phosphate buffer solutions[J]. Pharm Res, 2001, 18(1): 90-97.
[9] STRICKLEY R G, VISOR G C, LIN L H, et al. An unexpected pH effect on the stability of moexipril lyophilized powder[J]. Pharm Res, 1989,36(6):971-975.
[10] RAMPRAKASH G, KOUSTUV C, LARRY G, et al. Impact of freeze-drying on ionization of sulfonephthalein probe molecules in trehalose-citrate systems[J]. J Pharm Sci, 2010, 95(7):1498-1510.
[11] HAIKALA R, EEROLA R, TANNINEN V P, et al. Polymorphic changes of mannitol during freeze-drying: effect of surface-active agents[J]. PDA J Pharm Sci Technol, 1997, 51(2): 96-101.
[12] GOVINDARAJAN R, CHATTERJEE K, GATLIN L, et al. Impact of freeze-drying on ionization of sulfonephthalein probe molecules in trehalose-citrate systems[J]. J Pharm Sci, 2006, 95(7):1498-1510.
[13] TELANG C, SURYANARAYANAN R. Crystallization of cephalothin sodium during lyophilization from tert-butyl alcohol-water cosolvent system[J]. Pharm Res, 2005, 22(1):153-160.
[14] LOFTSSON T, BREWSTER M E. Pharmaceutical applications of cyclodextrins.1.Drug solubilization and stabilization[J]. J Pharm Sci, 1996, 85(10):1017-1025.
[15] GOULD S, SCOTT R C. 2-Hydroxypropyl-beta-cyclodextrin(HP-beta-CD):atox-icologyreview[J]. Food Chem Toxicol, 2005, 43(10):1451-1459.
[16] National Medical Products Administration. Announcement on Further Improving Related Issues Concerning Drug Review and Approval and Supervision Work (Draft for Comment) [EB/OL]. [2017-12-22]. http://www.nmpa.gov.cn/WS04/CL2101/336058.html.
[17] RAVIN H A, SELIGMAN A M, FINE J. Polyvinyl pyrrolidone as a plasma expander[J]. New Engl J Med, 1952, 247(24):921-929.
[18] FEDERAL REGISTER, VOL. 43, NO. 68-FRIDAY, APRIL 7, 1978. [EB/OL]. [2018-11-19]. https://s3.amazonaws.com/archives.federalregister.gov/issue_slice/1978/4/7/14742-14744.pdf#page=2.
[19] European Medicines Agency. Guideline, Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use. [EB/OL]. [2018-11-19] . https://www.ema.europa.eu/en/documents/scientific-guideline/draft-information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human_en.pdf.
[20] HERMAN B D, SINCLAIR B D, MILTON N, et al. The effect of bulking agent on the solid-state stability of freeze dried methylprednisolone sodium succinate[J]. Pharm Res, 1994, 11(10): 1467-1473.
[21] SERIGO A, RAMBHATLA S, PIKAL M J. Heat and mass transfer scale-up issues during freeze drying, I: atypical radiation and the edge vial effect[J]. AAPS Pharm Sci Tech, 2003, 4(2):114-127.
[22] LAM T, STRICKLY R G, VISOR G C. An unexpected pH effect on stability of moexipril lyophilized powder[J]. Pharm Res, 2004, 6(11):971-975.
[23] KASPER J C, WINTER G, FRIESS W. Recent advances and further challenges in lyophilization[J]. Eur J Pharm Biopharm, 2013, 85(2):162-169.
[24] The Drug Evaluation Center of National Medical Products Administration. Notice on Publicly Soliciting Opinions on Technical Requirements for Consistency Evaluation of Listed Chemical Generic Drugs (Injections) [EB/OL]. [2017-12-22] .http://www.cde.org.cn/news.do?method=viewInfoCommon&id=314268.
[25] LU E, EWING S, GATLIN L, et al. The effect of bulking agents on the chemical stability of acid-sensitive compounds in freeze-dried formulations: sucrose inversion study[J]. J Pharm Sci, 2009, 98(9):3387-3396.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(3392 KB)
